Commonwealth Equity Services
BIB icon

Commonwealth Equity Services’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Commonwealth Equity Services’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-6,147
Closed -$251K – 2245
2016
Q1 		$251K Buy
+6,147
New +$272K ﹤0.01% 1760

Other funds holding BIB

RIA
RPG Investment Advisory Pleasanton, California $829M AUM 36.68% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TH
Timber Hill Greenwich, Connecticut $15.4M AUM 30.7% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
ICAS
Investors Capital Advisory Services Lynnfield, Massachusetts $521M AUM 1.51% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Commonwealth Equity Services's BIB Position: Q2 2016 in Review

Commonwealth Equity Services sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q2 2016, closing a stake of 6,147 shares — an estimated $251K sold.

Commonwealth Equity Services first reported a position in BIB in Q1 2016 and held it in 1 quarter. The position peaked at $251K in Q1 2016. 31 funds tracked by Wall St. Rank hold BIB as of Q2 2016.

  • Commonwealth Equity Services reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q2 2016 after selling out during the quarter.
  • Commonwealth Equity Services sold 6,147 ProShares Ultra NASDAQ Biotechnology shares in Q2 2016, an estimated $251K.
  • Commonwealth Equity Services first reported a position in ProShares Ultra NASDAQ Biotechnology in Q1 2016 and held it in 1 quarter.
  • Commonwealth Equity Services's ProShares Ultra NASDAQ Biotechnology position peaked at $251K in Q1 2016.
  • 31 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q2 2016.

Based on Commonwealth Equity Services's 13F filing for Q2 2016, filed 4 Aug 2016.